HIF-1 as a target for drug development
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, growing evidence showed that the strong cell–cell contacts of tumor spheroids in combination with dense ECM deposition is responsible for chemoresistance by posing a physical barrier to the penetration of chemotherapeutics and immune cells similar to in vivo.[ 48 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [48]
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Most importantly, overexpression of HIF-1α or HIF-2α have been implicated as poor prognostic indicators for a variety of tumour”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“Although the role of HIF-1α in human tumours remains correlative, in transplanted tumours in immunodeficient mice, loss of HIF-1α or HIF-1β results in reduced tumour growth, decreased angiogenesis and increased responsiveness to radiotherap”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Research works printed but not linked: 1
- Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206–210 (1997). · DOI · Paper page
Cited by
Items 501–600 of 671
Yang, E., Fan, X., Ye, H., Sun, X., Ji, Q., Ding, Q., Zhong, S., Zhao, S., Xuan, C., Fang, M., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04890-9 · Cited by 5
“Reducing HIF-1 levels can disrupt multiple pathways, including cell survival, glucose metabolism, invasion, and angiogenesis [113].”
BackgroundHIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition
Geng, H., Ko, H., Pittsenbarger, J., Harvey, C. T., Xue, C., Liu, Q., Wiens, S., Kachhap, S. K., Beer, T. M., & Qian, D. Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.724059 · Cited by 6
“Thus, HIF1α is considered as a promising therapeutic target, which in theory may improve disease outcome and patient survival (Giaccia et al., 2003; Semenza, 2003; Powis and Kirkpatrick, 2004).”
BackgroundHypoxia reduces SLC27A5 to promote hepatocellular carcinoma proliferation by repressing HNF4A
Tao, J., Liu, Y., Tang, X., Nie, D., Wu, K., Wang, K., & Tang, N. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.119916 · Cited by 5
Hypoxia, Metastasis, and Antiangiogenic Therapies
Siemann, D. W., Dai, Y., & Horsman, M. R. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9167-5_9 · Cited by 5
Cassiano, C., Morretta, E., Costantini, M., Fassi, E. M. A., Colombo, G., Sattin, S., & Casapullo, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105258 · Cited by 5
Regulation of Second Messenger Systems and Intracellular Pathways
Merighi, S., Simioni, C., Lane, R., & IJzerman, A. P. (2009) · Springer eBooks · doi:10.1007/978-90-481-3144-0_4 · Cited by 5
“Overexpression of HIF-1a protein has been reported in several human cancers, where it has been positively associated with tumor progression, treatment failure, and poor survival ( Giaccia et al. 2003; Semenza 2003).”
BackgroundJagodzinski, N., Leichtle, A., Depping, R., Plötze‐Martin, K., Hakim, S. G., Bruchhage, K., & Pries, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-97314-7 · Cited by 4
“In this context, HIF-related transcriptional activation is closely associated with cardiovascular, metabolic, inflammatory, and infection-related diseases 40–42 , whereas HIF-1α hydroxylation under normoxia conditions inhibits the recruitment of involved transcriptional coactivators 43 .”
Wang, C., Cui, X., Lv, L.-X., Wang, W.-H., Jing, Q.-Q., Yin, J.-N., Cao, X.-Z., Wei, M., Lu, L., & Shao, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01859 · Cited by 4
Khaket, T. P., Rimal, S., Chavda, V. K., & Lu, B. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218354 · Cited by 4
Gharehbaba, A. M., Soltanmohammadi, F., Eskandani, M., & Adibkia, K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125979 · Cited by 8
Boticario, C. B., & Angosto, M. C. (2010) · Anales de la Real Academia Nacional de Farmacia · Cited by 11
HILPDA, a new player in NASH-driven HCC, links hypoxia signaling with ceramide synthesis
Fernández-Checa, J. C., Torres, S., & García‐Ruiz, C. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.009 · Cited by 4
2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α
Cheng, J., Hu, L., Yang, Z., Suo, C., Wang, Y. J., Gao, P., Cui, C., & Sun, L. (2019) · Cells · doi:10.3390/cells8050439 · Cited by 6
Search for Medicinal Seeds from Marine Organisms
Arai, M., & Kobayashi, M. (2010) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.68.470 · Cited by 4
Miscellaneous small- molecule and biological approaches to targeted cancer therapy
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00016-9 · Cited by 6
Antiangiogenic Alkaloids from Plants
Lopes, F. C. M., Regasini, L. O., Alçada, M. N. M. P., & Soares, R. A. (2013) · Springer eBooks · doi:10.1007/978-3-642-22144-6_48 · Cited by 4
HCS strategy targeting dysregulation of the VHL/HIF pathway for drug discovery
Cautain, B., de Pedro, N., de Escalona, M. M., Tormo, J. R., Genilloud, O., & Vicente, F. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.43053 · Cited by 5
“The strategy was thus to validate the concept of specifically targeting the loss of the VHL tumor suppressor gene though pharmacologic means [11-14].”
BackgroundLiu, X., Li, X., Yang, F., Li, Y., Jiao, X., & Xie, P. (2018) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2018.1473386 · Cited by 4
Krishnan, A. V., & Feldman, D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-381978-9.10086-1 · Cited by 8
Natural Products as Probes of Selected Targets in Tumor Cell Biology and Hypoxic Signaling
Nagle, D. G., & Zhou, Y. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00054-x · Cited by 5
Lin, L., Deng, L., & Bao, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307954 · Cited by 3
Discovery of KRAS-G12D degraders via exploration of various E3 ligases
Yim, H., Song, X., Zhong, Y., Hu, J., Xiong, Y., & Jin, J. J. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118635 · Cited by 3
Chapter 13 Oxygen as a Direct and Indirect Biological Determinant in the Vasculature
Huang, Y., & Giordano, F. J. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(08)02813-9 · Cited by 4
Can Irradiated Tumors Take NO for an Answer?
Johnson, R. S., & Huang, E. L. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.04.008 · Cited by 3
Self-citationPathobiology of True Arteriovenous Malformations
Gavin, C. G., & Kitchen, N. D. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5316-3.00386-5 · Cited by 3
Role of Hypoxia-Inducible Factor (HIF) in the Initiation of Cancer and Its Therapeutic Inhibitors
Eda, S. R., Vadde, R., & Jinka, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-6728-0_10 · Cited by 3
Molecular Signaling Pathways in Nasopharyngeal Cancer
Le, Q., & Lu, J. J. (2010) · Medical radiology · doi:10.1007/978-3-540-92810-2_3 · Cited by 3
HIF-1-regulated glucose metabolism in the control of apoptosis signaling
Fulda, S. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.3.303 · Cited by 3
ATF4 and HIF-1α in bone: An intriguing relationship
Schipani, E., Mangiavini, L., & Merceron, C. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2045 · Cited by 3
“Hypoxia-inducible factor-1 (HIF-1), a ubiquitously expressed transcription factor, is a major regulator of cellular adaptation to hypoxia (12-18).”
Hypoxia-Inducible Factor-1 Signaling System
Stroka, D., & Candinas, D. (2009) · Springer eBooks · doi:10.1007/978-3-642-00150-5_27 · Cited by 3
Are cancer stem cells concentrated in more alkaline hypoxic regions of tumors?
Anderson, K. M., Jajeh, A., Guinan, P., & Rubenstein, M. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.11.027 · Cited by 3
“Targeting members of the HIF family either directly or their associated activities is under study [26–28].”
BackgroundDiscovery of Novel Transcription Factor Inhibitors Using a Pyrazole-based Small Molecule Library
Ha, H. (2008) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2008.29.2.323 · Cited by 3
Hypoxia, Angiogenesis, and Oral Cancer Metastasis
Le, Q., Courter, D. L., & Giaccia, A. J. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0775-2_14 · Cited by 3
“Adaptation of cells to an anaerobic environment is achieved by the transcriptional induction of genes that are involved in glycolysis, hematopoiesis, angiogenesis, invasive capacity, and regulating vascular tone, as well as a number of other functions ( Giaccia et al. 2003 ).”
BackgroundSelf-citationKeith, B., & Simon, M. C. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10018-4 · Cited by 4
Vetrovoy, O. V., Nimiritsky, P., Tyulkova, E. I., & Rybnikova, E. A. (2021) · Cell and Tissue Biology · doi:10.1134/s1990519x21020127 · Cited by 3
“In particular, in addition to prolyl hydroxylase, there is also an asparagine hydroxylase pathway of inhibition of HIF1 transcription activity (Giaccia et al., 2003; Kaspe et al., 2006).”
BackgroundTargeting HIF-α: when a magic arrow hits the bull's eye
Huang, E. L. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03227-1 · Cited by 3
Pharmacological revascularisation in coronary and peripheral vascular disease
Tarzami, S. T., & Singh, J. P. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.10.1319 · Cited by 3
“HIF-1α is a key physiological oxygen sensor [47].”
BackgroundElectrolytic patterning of dissolved oxygen microgradients during cell culture
Park, J. H., Bansal, T., Chueh, B.-H., Takayama, S., & Maharbiz, M. M. (2005) · IEEE International Conference on Micro Electro Mechanical Systems (MEMS) · doi:10.1109/memsys.2005.1454061 · Cited by 4
Impact of Tumor Hypoxia, Src, and Met Signaling in the Dissemination of Tumor Cells
Dai, Y., Shi, W., Molnar, N., & Siemann, D. W. (2011) · Springer eBooks · doi:10.1007/978-94-007-2558-4_7 · Cited by 3
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0024-x · Cited by 5
Drug Design Methods to Regulate Protein–Protein Interactions
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_6 · Cited by 4
Therapeutic Strategies that Target the HIF System
Cook, K. M., & Schofield, C. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-71518-6_32 · Cited by 2
Hypoxia and the hypoxia-inducible factors in the skeleton
Schipani, E., & Clemens, T. L. (2008) · IBMS BoneKEy · doi:10.1138/20080329 · Cited by 3
“the central regulator of the hypoxic response in mammals (3-7).”
BackgroundGriffiths, J. R., & Stubbs, M. (2007) · Humana Press eBooks · doi:10.1385/1-59259-893-5:135 · Cited by 2
“Because of the crucial role of HIF-1 and its link with the metabolic phenotype in tumors (7), HIF-1 presents an attractive target for drug therapy, and a number of studies have already been reported (33, 34 ).”
Backgroundhypoxia by HIF-1 Transcriptional regulation of vascular endothelial cell responses to
Garcia, J. G. N., Semenza, G. L., Manalo, D. J., Rowan, A., Lavoie, T. L., Natarajan, L., Kelly, B., & Ye, S. Q. (2013) · Cited by 2
Xie, G.-H., Xie, W., Piao, H., & Li, D. (2019) · International Journal of Pharmacology · doi:10.3923/ijp.2019.361.369 · Cited by 2
Khoei, S. G., Hosseini, N. F., & Najafi, R. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1732966 · Cited by 2
Replicating Viruses for Brain Tumor Treatment
Jiang, H., McCormick, F. P., Gomez‐Manzano, C., Curiel, D. T., Lang, F. F., Yung, W., & Fueyo-Margareto, J. (2006) · CRC Press eBooks · doi:10.3109/9781420016390-16 · Cited by 2
The Cellular Microenvironment and Metastases
Giaccia, A. J., & Erler, J. T. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50006-3 · Cited by 2
Self-citationHIF1α is dispensable for oocyte development and female fertility in mice
Chen, Y., Du, S., Huang, Z., Han, L., & Wang, Q. (2022) · PeerJ · doi:10.7717/peerj.13370 · Cited by 2
“An evolutionarily conserved pathway mediated by oxygen-dependent posttranslational hydroxylation of a transcription factor called hypoxia-inducible factor (HIF) plays a pivotal role in this process ( Giaccia, Siim & Johnson, 2003 ).”
Other Nonbiological Approaches to Targeted Cancer Chemotherapy
Avendaño, C., & Menéndez, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-62649-3.00011-9 · Cited by 3
Finan, P. M., & Ward, S. G. (2006) · Humana Press eBooks · doi:10.1385/1-59259-962-1:053 · Cited by 3
“HIF-1 regulates the expression of a wide variety of genes central to angiogenesis, including VEGF and the VEGF receptor, and functions as a sensor of oxygen balance ( 82 ).”
BackgroundShi, L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc271 · Cited by 2
Hypoxia inducible factor: targeted anticancer prodrug
Wang, Y. (2007) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t37h1jz0 · Cited by 2
Torres, S., Fernández-Checa, J. C., & García‐Ruiz, C. (2022) · Exploration of Digestive Diseases · doi:10.37349/edd.2022.00012 · Cited by 1
Aglycemia induces apoptosis under hypoxic conditions in A549 cells
Keçeci, Y. Ö., & İncesu, Z. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3983 · Cited by 1
“7,8 However, there are also reports that HIF induces apoptosis.”
BackgroundFebrônio, E. M., Secaf, A. D. F., Chahud, F., Elías, J., dos Reis, R. B., & Muglia, V. F. (2025) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001707 · Cited by 1
Zhang, C., Deng, D., Feng, H., Jiang, S., Song, Z., Zhang, K., Fu, L., & Yin, S. (2025) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2025.110436 · Cited by 2
Theodoraki, M., Hofmann, L., Bauer, H. F., Fleckner, J., Depping, R., Idel, C., Plötze‐Martin, K., Penxová, Z., Rades, D., Hoffmann, T. K., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1701388 · Cited by 1
“…in different innate immune cells and are the key regulators to facilitate the cellular response to hypoxic conditions in different in fl ammatory and malignant diseases (36 – 40), whereas the recruitment of these transcriptional coactivators is prevented under normoxic conditions (41 – 44).”
de Melo, N. C., Accioli, G. S., Sánchez-Luquez, K., Gomes, M. F. D. F., Felicio, A. C., & de Carvalho, L. M. (2026) · ACS Omega · doi:10.1021/acsomega.5c12757 · Cited by 1
Hypoxia in Head and Neck Cancers: Clinical Relevance and Treatment
Tao, Y., & Bourhis, J. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9464-6_10 · Cited by 1
“HIF-1a protein synthesis is regulated via O 2 -independent mechanisms, by the activation of the phosphatidylinositol 3-kinase (PI3K) and ERK-mitogen-activated protein kinase (MAPK) pathways [ 8 ].”
BackgroundThe Role of Tumor Hypoxia in Head and Neck Cancer Radiotherapy
Le, Q., Giaccia, A. J., & Brown, J. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-938-7_10 · Cited by 1
Self-citationHypoxia and Radioresistance in Head and Neck Cancer
Kuo, P., & Le, Q. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8815-6_14 · Cited by 1
“Numerous inhibitors have been developed to block HIF-1, including the attenuation of protein stability and accumulation (17-AAG, 17-DMAG, Trichostatin, LAQ824, RAD001, CCI-799, rapalogs, LY294002, 2ME2, PEITC) as well as HRE binding and transcriptional activity (Echinomycin, Polyamide, Flavorpiridol, Chetomin) [79], […”
BackgroundThe Role of Hypoxia-Induced Factors
Schipani, E., & Khatri, R. (2010) · Springer eBooks · doi:10.1007/978-1-84882-822-3_7 · Cited by 1
“Hypoxia-inducible factor-1 (Hif-1), a ubiquitously expressed transcription factor, is a major regulator of cellular adaptation to hypoxia [14, 38, 65, 88, 130] (Fig.”
BackgroundDiscovery of a Small Molecule Activator of the Hypoxia Inducible Factor Pathway
Thériault, J. R., Perez, J. R., Gilbert, S. R., Palmer, M. A. J., Schreiber, S. L., Lindsley, C. W., Dawson, E. S., Engers, J. L., Felts, A. S., Bates, B. S., et al. (2013) · Europe PMC (PubMed Central) · Cited by 1
Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation
Ahn, G., & Brown, J. M. (2006) · Springer eBooks · doi:10.1007/3-540-35662-2_5 · Cited by 1
Gupta, E., Santos, N., Liu, Y., Havre, P. A., Dang, N. H., Luesch, H., & Dang, L. H. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.46129 · Cited by 1
“To date, high-throughput small-compound screens and mechanistic studies have identified several classes of anticancer agents that disrupt HIF-α function, including inhibition of its transcriptional activity and HIF-α protein synthesis or stability [31-34].”
BackgroundAdhesion-Mediated Signalling in Cancer: Recent Advances and Mathematical Modelling
Crociani, O., Becchetti, A., Fanelli, D., & Arcangeli, A. (2014) · Biophysical Reviews and Letters · doi:10.1142/s1793048014300047 · Cited by 1
Flett, T., Campbell, E., Phillips, E., Vissers, M. C. M., & Dachs, G. U. (2014) · Biomedicines · doi:10.3390/biomedicines2010098 · Cited by 1
“HIF-1 inhibition has been suggested as a therapeutic strategy in cancer and HIF-1α is actively being validated as a drug target in clinical trials [6].”
BackgroundOligooxopiperazines as Topographical Helix Mimetics
Lao, B. B., & Arora, P. S. (2016) · Topics in heterocyclic chemistry · doi:10.1007/7081_2015_195 · Cited by 1
Chánez‐Cárdenas, M. E., Espinoza-Rojo, M., Rivera-Rodriguez, J. A., & Aguilera, P. (2011) · Current Signal Transduction Therapy · doi:10.2174/157436211795660061 · Cited by 1
Tocotrienols, Inflammation, and Cancer: How Are They Linked?
Prasad, S., Sung, B., Patchva, S., Gupta, S. C., & Aggarwal, B. B. (2012) · CRC Press eBooks · doi:10.1201/b12502-16 · Cited by 1
Replicating Viruses for Brain Tumor Treatment
Jiang, H., McCormick, F. P., Gomez‐Manzano, C., Curiel, D. T., Lang, F. F., Yung, W. K. A., & Fueyo-Margareto, J. (2016) · doi:10.3109/9781420016390-19 · Cited by 1
Ran, G., Wang, Y., Liu, H., Wei, C., Zhu, T., Wang, H., He, H., & Liu, X. (2017) · Disease Markers · doi:10.1155/2017/9506527 · Cited by 1
Analysis of the binding mode of a novel HIF1α inhibitor through molecular modelling
Zhao, Y., Li, Y., Wang, J. H., Zhang, J., & Zhang, X. (2018) · General Physiology and Biophysics · doi:10.4149/gpb_2017036 · Cited by 1
“However, due to the intrinsic challenges associated with the discovery and development of pharmacological inhibitors of transcription factors, such as the lack of specificity, currently there is no Food and Drug Administration (FDA) approved drug (Giaccia et al. 2003; Onnis et al. 2009; Chen et al. 2014).”
BackgroundHypoxia-Inducible Factor-1 Signaling System
Stroka, D., & Candinas, D. (2005) · Springer eBooks · doi:10.1007/3-540-27194-5_26 · Cited by 1
The importance of the multiple target action of green tea polyphenols for neuroprotection
Silvia, A. M. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/286 · Cited by 1
Joshi, S., Painuli, S., Misra, K., Kumar, N., Bachheti, R. K., Rai, N., & Singab, A. N. B. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300249 · Cited by 1
Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma
Jonsson, G., Oliveira, T., Hofmann, M., Lemberger, U. J., Stejskal, K., Krššáková, G., Sakic, I., Novatchkova, M., Mereiter, S., Grabmann, G., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00498-2 · Cited by 1
“…making up approximately 80% of all RCC cases, and also the deadliest [1, 2]. ccRCC is primarily driven by loss-of-function mutations or epigenetic silencing of the Von Hippel Lindau (VHL) tumor suppressor, leading to the initiation of a genetic hypoxia program which drives tumor progression [3, 4].”
Signalisation par l’oxygène et l’oxyde nitrique
Robert, J. (2010) · Springer eBooks · doi:10.1007/978-2-8178-0028-8_17 · Cited by 1
Molecular Targeting in Hepatocellular Carcinoma
Schwartz, J. D., & Llovet, J. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-337-0_8 · Cited by 1
Controlled Oxygen Activation in Human Oxygen Sensor FIH
Saban, E. (2011) · Scholarworks (University of Massachusetts Amherst) · doi:10.7275/2395887 · Cited by 2
Compositional Correlation for Detecting Real Associations Among Time SeriesPreprint
Dikbaş, F. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1801.05029 · Cited by 1
A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY
Buolamwini, J. K. (2006) · Elsevier eBooks · doi:10.1016/b978-012088561-9/50002-8
Signalling by Oxygen and Nitric Oxide
Robert, J. (2014) · Springer eBooks · doi:10.1007/978-3-319-14340-8_16
Selenium as a Modulator of Efficacy and Toxicity of Chemotherapy and Radiation
Lobb, R. J. (2011) · Research Commons (University of Waikato)
HIF-INDEPENDENT RESPONSES IN HYPOXIA
Padmanabha, D. (2015) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/pyjy-pw08
“Some of the promising interventions for anti-cancer therapies involve mechanism for downregulating HIF-1, either by inhibiting translation or promoting degradation, or inhibiting key HIF target genes, such as VEGFA (Giaccia et al., 2003).”
BackgroundHypoxia Inhibits DNA Repair to Promote Malignant Progression
Eric, L., Yoo, Y., Koshiji, M., & Kenneth, K. W. (2011) · InTech eBooks · doi:10.5772/24825
“Many studies have indicated that hypoxia promotes tumor metabolism, angiogenesis, and metastasis (Bertout et al, 2008; Giaccia et al, 2003; Harris, 2002; Semenza, 2003).”
BackgroundEffect of a HIF-1 Alpha Polymorphism on the Incidence and Prostate Cancer
Bubley, G. J. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada470130
Evangelista, M. J. D. A. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2013.tde-05022014-115549
The Expression and Function of PPAR and HIF-1 in Human Melanoma
Mills, C. N. (2007)
Acute regulation of skeletal muscle protein metabolism by nutrients, exercise and hypoxia
Etheridge, T. (2010) · University of Brighton Repository (University of Brighton)
Targeting hypoxia-inducible factor-1 for therapy and prevention
Zhong, H. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.7.951
“A better understanding of specific biological phenomenon under hypoxic conditions results in a continuing appreciation of targeting HIF-1 for therapy [3,76], as HIF-1 is a bona fide ‘master’ that controls homeostasis under hypoxic conditions.”
BackgroundEffects of copper on the acute ventilatory drive of killifish, Fundulus heteroclitus
Baker, S. J. C. (2016) · MacSphere (McMaster University) · doi:10.71548/7884 · Cited by 2
The Biological Role of Factor-Inhibiting Hypoxia- Inducible Factor
Khan, M. N. (2008) · Spiral (Imperial College London) · doi:10.25560/4645
Identification of Novel HIF1A Target Genes That Regulate Tumor Progression and Metastasis
Peacock, D. L. (2013) · doi:10.21007/etd.cghs.2013.0241 · Cited by 1
Doerr, M. D. (2014) · The Atrium (University of Guelph)
Development of bioreductive inhibitors of checkpoint kinase 1 to target hypoxic tumours
Körner, C. (2015) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-jx9bvgek4
Inhibition of Breast Cancer Angiogenesis and Metastasis ay Targeting Hypoxia-Inducible Factor-1α
Madu, C. O. (2012) · doi:10.21007/etd.cghs.2012.0192
“Although numerous drugs were developed to primarily target signal transduction proteins, these drugs were later discovered to inhibit HIF-1 either in conjunction with, or as a consequence of inhibiting their primary target [19, 20, 118-122].”
BackgroundCharacterization of a Novel Dendritic Cell Population
Mikhailova, A. (2012) · TSpace (University of Toronto)
Metadata
- Authors
- Giaccia, A., Siim, B. G., & Johnson, R. S.
- Affiliations
- Stanford Medicine (US)
- University of Auckland (NZ)
- University of California San Diego (US)
- Corresponding author
- Johnson, Randall S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-10-01
- Volume
- 2
- Issue
- 10
- Pages
- 803-811
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2075880922
- Cited by
- 631
- References
- 116
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 10 · 2023: 21 · 2022: 26 · 2021: 19 · 2020: 30 · 2019: 14 · 2018: 26 · 2017: 16 · 2016: 20 · 2015: 20 · 2014: 27 · 2013: 30 · 2012: 29
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-1, hypoxia-inducible factor, hypoxia, therapeutic target, oxygen sensing, transcriptional regulation, cancer, heart disease, stroke, therapeutic targeting
- MeSH terms
- Animals, Cardiovascular Diseases, DNA-Binding Proteins, Gene Expression Regulation, Humans, Neoplasms, Nuclear Proteins, Oxygen, Transcription Factors, Drug Design, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.